益气培元颗粒改善急性肾损伤短期预后的多中心双盲随机对照试验
本研究为多中心、双盲、安慰剂对照随机试验,纳入144例成人急性肾损伤患者,评估益气培元颗粒(每次36g,每日2次,共28天)对短期预后的疗效与安全性。总体分析114例,第4周和第24周eGFR及Scr变化组间无差异;亚组分析显示第4周eGFR平均变化益气培元组为27.39 mL/min/1.73 m2,安慰剂组为5.78 mL/min/1.73 m2,组间平均差21.61 mL/min/1.73 m2(P < 0.001),复合终点事件发生率分别为59.1%和16.1%(P = 0.002)。结论认为益气培元颗粒可有效改善急性肾损伤发病4周后的肾功能。
要点
- 益气培元颗粒每次36g、每日2次、共28天,用于成人急性肾损伤。
- 总体分析eGFR和Scr变化组间无差异。
- 亚组分析第4周eGFR改善益气培元组优于安慰剂组。
核心结论
- 益气培元颗粒可有效改善急性肾损伤患者发病4周后的肾功能。
- 益气培元颗粒可能成为成人急性肾损伤有前景的疗法。
研究设计与样本
- 前瞻性、双盲、多中心、随机、安慰剂对照临床试验。
- 共纳入144例成人急性肾损伤患者,随机分为两组。
- 益气培元组接受益气培元颗粒36g每日2次共28天,安慰剂组接受同剂量安慰剂。
- 主要结局为基线至治疗第4周和第24周eGFR的变化。
- 共114例患者数据纳入分析(益气培元组59例,对照组55例)。
主要发现
- 第4周和第24周eGFR及Scr平均变化两组间无差异。
- 亚组分析(益气培元组22例,安慰剂组31例)中,治疗4周后eGFR平均变化益气培元组为27.39 mL/min/1.73 m2,安慰剂组为5.78 mL/min/1.73 m2,组间平均差21.61 mL/min/1.73 m2(P < 0.001)。
- 干预期间,益气培元组和安慰剂组分别报告2例和4例严重不良事件。
关键数值与推荐
- 主要结局:基线至治疗第4周和第24周eGFR的变化。
- 次要结局:基线至治疗后Scr变化及终点事件发生率,终点事件定义为eGFR较基线增加超过25%、eGFR >75 mL/min per 1.73 m2或复合终点(满足上述任一标准者之和)。
- 益气培元颗粒用法:36g,每日2次,共28天。
临床怎么用
- 对于成人急性肾损伤患者,可考虑在常规治疗基础上加用益气培元颗粒以改善短期肾功能。
- 使用时应参照试验方案:每次36g、每日2次、连续28天。
- 需关注严重不良事件,试验中益气培元组报告2例、安慰剂组4例。
局限性
- 总体分析未显示eGFR和Scr变化组间差异,阳性结果主要来自亚组分析。
- 亚组样本量较小(益气培元组22例,安慰剂组31例),结果需谨慎解读。
- 分析数据仅114例,低于随机入组的144例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Yiqi Peiyuan (YQPY) prescription, a composite prescription of traditional Chinese medicine, has been used to prevent or delay the continued deterioration of renal function after acute kidney injury (AKI) in some institutions and has shown considerable efficacy. OBJECTIVE: This is the first randomized controlled trial to assess efficacy and safety of YQPY for improving short-term prognosis in adult patients with AKI. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a prospective, double-blind, multicenter, randomized, and placebo-controlled clinical trial. A total of 144 enrolled participants were randomly allocated to two groups according to a randomization schedule. Participants, caregivers and investigators assessing the outcomes were blinded to group assignment. Patients in the YQPY group received 36 g YQPY granules twice a day for 28 days. Patients in the placebo group received a placebo in the same dose as the YQPY granules. MAIN OUTCOME MEASURES: The primary outcome was the change in the estimated glomerular filtration rate (eGFR) between baseline and after 4 and 24 weeks of treatment. The secondary outcomes were the change of serum creatinine (Scr) level between baseline and after treatment, and the incidence of endpoint events, defined as eGFR increasing by more than 25% above baseline, eGFR >75 mL/min per 1.73 m2 or the composite endpoint, which was defined as the sum of patients meeting either of the above criteria. RESULTS: Data from a total of 114 patients (59 in the YQPY group and 55 in the control group) were analyzed. The mean changes in eGFR and Scr in weeks 4 and 24 had no difference between the two groups. In further subgroup analysis (22 in the YQPY group and 31 in the control group), the mean change in eGFR after treatment for 4 weeks was 27.39 mL/min per 1.73 m2 in the YQPY group and 5.78 mL/min per 1.73 m2 in the placebo group, and the mean difference between groups was 21.61 mL/min per 1.73 m2 (P < 0.001). Thirteen (59.1%) patients in the YQPY group and 5 (16.1%) in the placebo group reached the composite endpoints (P = 0.002). During the intervention, 2 and 4 severe adverse events were reported in the YQPY and placebo groups, respectively. CONCLUSION: The YQPY granules can effectively improve the renal function of patients 4 weeks after the onset of AKI, indicating that it has good efficacy for improving short-term renal outcomes in patients with AKI. The YQPY granules may be a promising therapy for adults with AKI. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100051723. Please cite this article as: Wu JJ, Zhang TY, Qi YH, Zhu MY, Fang Y, Qi CJ, Cao LO, Lu JF, Lu BH, Tang LM, Shen JX, Mou S. Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: a multicenter, double-blind, placebo-controlled, randomized trial. J Integr Med. 2024; 22(3): 279-285.
引用
- Wu JJ, Zhang TY, Qi YH, et al. Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: A multicenter, double-blind, placebo-controlled, randomized trial. J Integr Med. 2024. PMID: 38688809. doi:10.1016/j.joim.2024.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。